MASSACHUSETTS GENERAL HOSPITAL
DEPARTMENT OF ORTHOPAEDIC SURGERY

GRAND ROUNDS

Michelle Ghert, MD, FRCSC
Professor, Department of Surgery, Division of Orthopaedic Surgery
McMaster University
Hamilton, Ontario, Canada

“Randomized Controlled Trials in Orthopaedic Oncology”

Thursday, May 25, 2023
6:30am -7:30am EST

Massachusetts General Hospital
O’Keeffe Auditorium
(HYBRID, In-person & on Zoom)
Michelle Ghert, MD, FRCSC studied Medicine at Vanderbilt University in the United States and completed her orthopaedic surgery residency at Duke University. She then studied at the University of Toronto for her fellowships in orthopaedic oncology and cancer research. She was appointed as Assistant Professor at McMaster University in 2005 and was promoted to Full Professor in 2017.

She has led the Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) international randomized controlled trial (RCT), which was the first multicenter RCT in orthopaedic oncology. The study randomized 604 patients undergoing lower extremity endoprosthetic reconstruction of oncologic reasons to one or five days of postoperative prophylactic intravenous antibiotics. Patients were enrolled across 48 clinical sites in 12 countries and 6 continents. The study found that there was no difference in surgical site infections between randomized groups, but there was a significantly higher rate of antibiotic related complications in the five-day group. The PARITY study has won multiple collaboration and national research awards.

Dr. Ghert serves in the Presidential Line of the Musculoskeletal Tumor Society and as the inaugural Chair of the Strategies in Clinical Research Section of the Orthopaedic Research Society.